Ocular Therapeutix, Inc. $OCUL Shares Acquired by Allianz Asset Management GmbH

Allianz Asset Management GmbH grew its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 63.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 61,200 shares of the biopharmaceutical company’s stock after acquiring an additional 23,700 shares during the period. Allianz Asset Management GmbH’s holdings in Ocular Therapeutix were worth $568,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Ocular Therapeutix by 17.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 893 shares during the period. Trust Co. of Vermont raised its position in shares of Ocular Therapeutix by 16.1% in the second quarter. Trust Co. of Vermont now owns 7,200 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 1,000 shares during the period. Hsbc Holdings PLC raised its position in shares of Ocular Therapeutix by 8.1% in the first quarter. Hsbc Holdings PLC now owns 19,573 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 1,472 shares during the period. Brooklyn Investment Group raised its position in shares of Ocular Therapeutix by 151.5% in the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 3,155 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Ocular Therapeutix by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company’s stock worth $686,000 after acquiring an additional 5,156 shares during the period. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Stock Performance

Ocular Therapeutix stock opened at $11.55 on Tuesday. The firm has a 50 day simple moving average of $12.13 and a 200-day simple moving average of $10.27. Ocular Therapeutix, Inc. has a 1-year low of $5.78 and a 1-year high of $13.85. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.10 and a quick ratio of 10.02. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of -9.02 and a beta of 1.45.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. The firm had revenue of $13.46 million during the quarter, compared to analysts’ expectations of $13.12 million. During the same period last year, the company earned ($0.26) EPS. The business’s quarterly revenue was down 17.7% on a year-over-year basis. On average, analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on OCUL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Wednesday, October 8th. HC Wainwright upped their price target on shares of Ocular Therapeutix from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. Zacks Research upgraded shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 2nd. Scotiabank reduced their price target on shares of Ocular Therapeutix from $22.00 to $20.00 and set a “sector outperform” rating for the company in a research report on Wednesday, August 6th. Finally, Citigroup restated an “outperform” rating on shares of Ocular Therapeutix in a research report on Wednesday, October 1st. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Ocular Therapeutix presently has an average rating of “Moderate Buy” and an average price target of $22.63.

Insider Activity

In other news, insider Pravin Dugel sold 21,494 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $12.04, for a total value of $258,787.76. Following the completion of the sale, the insider owned 3,227,244 shares of the company’s stock, valued at $38,856,017.76. This represents a 0.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Peter Kaiser sold 9,653 shares of the stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $11.03, for a total transaction of $106,472.59. Following the completion of the sale, the insider directly owned 194,440 shares of the company’s stock, valued at approximately $2,144,673.20. This trade represents a 4.73% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 61,806 shares of company stock worth $727,648. Corporate insiders own 2.30% of the company’s stock.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.